Clinical Trials Logo

Clinical Trial Summary

The injuries induced by Human Papillomavirus (HPV) (anogenital condyloma mainly) are more frequent among transplanted patients due to their immunosuppression. These injuries are benign but they have a negative impact on the patients' quality of life. The initial treatment is topical and then surgical. The injuries can relapse, especially among transplanted patients. The modification of the immunosuppressant treatment with a switch to mTOR inhibitors (mammalian Target Of Rapamycin) has shown its efficacy in preventing the recurrence of squamous cell carcinomas or treating Kaposi's disease. By analogy, this therapeutic strategy can be sometimes put forward to transplanted patients with HPV-induced injuries. The principal objective of this study is to describe the evolution of HPV-induced lesions in solid organ transplant patients.


Clinical Trial Description

n/a


Study Design


NCT number NCT05198427
Study type Observational
Source Hospices Civils de Lyon
Contact
Status Completed
Phase
Start date February 14, 2022
Completion date March 31, 2022